Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Batoclimab phase 3 trial in generalized myasthenia gravis
2021-000249-42Phase 3Active
- Sponsor
- Immunovant, Inc.
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of batoclimab in myasthenia gravis (MG) (3 arms), sponsored by Immunovant, Inc. Primary endpoint: Change from Period 1 baseline in MG-ADL score to Week 12 for AChRAb+ participants. Started Sep 2022; status: active.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2021-000249-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000249-42.